Assessing the Risk of Bias in Randomized Clinical Trials With Large Language Models

被引:13
|
作者
Lai, Honghao [1 ,2 ]
Ge, Long [1 ,2 ,3 ]
Sun, Mingyao [4 ]
Pan, Bei [5 ]
Huang, Jiajie [6 ]
Hou, Liangying [5 ,7 ]
Yang, Qiuyu [1 ,2 ]
Liu, Jiayi [1 ,2 ]
Liu, Jianing [6 ]
Ye, Ziying [1 ,2 ]
Xia, Danni [1 ,2 ]
Zhao, Weilong [1 ,2 ]
Wang, Xiaoman [5 ]
Liu, Ming [5 ,7 ]
Talukdar, Jhalok Ronjan [7 ]
Tian, Jinhui [3 ,5 ]
Yang, Kehu [3 ,5 ]
Estill, Janne [5 ,8 ]
机构
[1] Lanzhou Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Lanzhou, Peoples R China
[2] Lanzhou Univ, Evidence Based Social Sci Res Ctr, Sch Publ Hlth, 199 Donggang West Rd, Lanzhou 730000, Peoples R China
[3] Key Lab Evidence Based Med & Knowledge Translat Ga, Lanzhou, Peoples R China
[4] Lanzhou Univ, Evidence Based Nursing Ctr, Sch Nursing, Lanzhou, Peoples R China
[5] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Peoples R China
[6] Gansu Univ Chinese Med, Coll Nursing, Lanzhou, Peoples R China
[7] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[8] Univ Geneva, Inst Global Hlth, Geneva, Switzerland
关键词
DOUBLE-BLIND; PRIMARY INSOMNIA; INTERRATER RELIABILITY; REBOUND INSOMNIA; WEIGHT-LOSS; LONG-TERM; RED MEAT; EFFICACY; SAFETY; DIET;
D O I
10.1001/jamanetworkopen.2024.12687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Large language models (LLMs) may facilitate the labor-intensive process of systematic reviews. However, the exact methods and reliability remain uncertain. Objective To explore the feasibility and reliability of using LLMs to assess risk of bias (ROB) in randomized clinical trials (RCTs). Design, Setting, and Participants A survey study was conducted between August 10, 2023, and October 30, 2023. Thirty RCTs were selected from published systematic reviews. Main Outcomes and Measures A structured prompt was developed to guide ChatGPT (LLM 1) and Claude (LLM 2) in assessing the ROB in these RCTs using a modified version of the Cochrane ROB tool developed by the CLARITY group at McMaster University. Each RCT was assessed twice by both models, and the results were documented. The results were compared with an assessment by 3 experts, which was considered a criterion standard. Correct assessment rates, sensitivity, specificity, and F1 scores were calculated to reflect accuracy, both overall and for each domain of the Cochrane ROB tool; consistent assessment rates and Cohen kappa were calculated to gauge consistency; and assessment time was calculated to measure efficiency. Performance between the 2 models was compared using risk differences. Results Both models demonstrated high correct assessment rates. LLM 1 reached a mean correct assessment rate of 84.5% (95% CI, 81.5%-87.3%), and LLM 2 reached a significantly higher rate of 89.5% (95% CI, 87.0%-91.8%). The risk difference between the 2 models was 0.05 (95% CI, 0.01-0.09). In most domains, domain-specific correct rates were around 80% to 90%; however, sensitivity below 0.80 was observed in domains 1 (random sequence generation), 2 (allocation concealment), and 6 (other concerns). Domains 4 (missing outcome data), 5 (selective outcome reporting), and 6 had F1 scores below 0.50. The consistent rates between the 2 assessments were 84.0% for LLM 1 and 87.3% for LLM 2. LLM 1's kappa exceeded 0.80 in 7 and LLM 2's in 8 domains. The mean (SD) time needed for assessment was 77 (16) seconds for LLM 1 and 53 (12) seconds for LLM 2. Conclusions In this survey study of applying LLMs for ROB assessment, LLM 1 and LLM 2 demonstrated substantial accuracy and consistency in evaluating RCTs, suggesting their potential as supportive tools in systematic review processes.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
    Hovmand, Oliver Rumle
    Poulsen, Emil Deleuran
    Arnfred, Sidse
    Storebo, Ole Jakob
    JOURNAL OF PSYCHOPHARMACOLOGY, 2023, 37 (07) : 649 - 659
  • [2] RISK OF BIAS ASSESSMENT OF CLINICAL TRIALS PUBLISHED IN IBEROAMERICAN UROLOGICAL JOURNALS
    Andres Garcia-Perdomo, Hemey
    Manuel Diaz-Hung, Andres
    Marina Mejia, Luz
    ARCHIVOS ESPANOLES DE UROLOGIA, 2015, 68 (07): : 615 - 626
  • [3] Comparing machine and human reviewers to evaluate the risk of bias in randomized controlled trials
    Armijo-Olivo, Susan
    Craig, Rodger
    Campbell, Sandy
    RESEARCH SYNTHESIS METHODS, 2020, 11 (03) : 484 - 493
  • [4] Efficacy of antidepressants: bias in randomized clinical trials and related issues
    Wang, Sheng-Min
    Han, Changsu
    Lee, Soo-Jung
    Jun, Tae-Youn
    Patkar, Ashwin A.
    Masand, Prakash S.
    Pae, Chi-Un
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (01) : 15 - 25
  • [5] Randomized clinical trials with run-in periods: frequency, characteristics and reporting
    Laursen, David Ruben Teindl
    Paludan-Mueller, Asger Sand
    Hrobjartsson, Asbjorn
    CLINICAL EPIDEMIOLOGY, 2019, 11 : 169 - 184
  • [6] Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors
    Hrobjartsson, Asbjorn
    Thomsen, Ann Sofia Skou
    Emanuelsson, Frida
    Tendal, Britta
    Hilden, Jorgen
    Boutron, Isabelle
    Ravaud, Philippe
    Brorson, Stig
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (04) : E201 - E211
  • [7] A new scale for assessing the quality of randomized clinical trials of psychotherapy
    Kocsis, James H.
    Gerber, Andrew J.
    Milrod, Barbara
    Roose, Steven P.
    Barber, Jacques
    Thase, Michael E.
    Perkins, Patrick
    Leon, Andrew C.
    COMPREHENSIVE PSYCHIATRY, 2010, 51 (03) : 319 - 324
  • [8] Assessing and minimizing risk of bias in randomized controlled trials of tobacco cessation interventions: Guidance from the Cochrane Tobacco Addiction Group
    Hartmann-Boyce, Jamie
    Lindson, Nicola
    ADDICTION, 2023, 118 (09) : 1811 - 1816
  • [9] An update on recent randomized clinical trials in systemic sclerosis
    Boleto, Goncalo
    Avouac, Jerome
    Allanore, Yannick
    JOINT BONE SPINE, 2021, 88 (05)
  • [10] Gender bias in clinical trials of biological agents for migraine: A systematic review
    Alonso-Moreno, Marta
    Rodriguez-de Francisco, Lupe
    Ciudad-Gutierrez, Pablo
    PLOS ONE, 2023, 18 (06):